Having trouble accessing articles? Reset your cache.

Pharmacyclics jumps on ibrutinib data

Pharmacyclics Inc. (NASDAQ:PCYC) jumped $20.84 (20%) to $125.90 on Tuesday after stopping early the Phase III RESONATE (PCYC-1112-CA) trial on the recommendation of an independent DMC after an interim analysis showed

Read the full 313 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE